Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefano Rusconi

Showing results (131-140 of 192) with videos related to

Pageof 20
Sort By:
AIDS (London, England)|January 26, 2026
Durable efficacy of dolutegravir/rilpivirine switch in subjects with HIV RNA <50 copies/mL and history of K103N mutationGraeme Moyle, Lambert Assoumou, Nathalie De Castro, et al.
AIDS (London, England)|August 16, 2020
Factors associated with hospital admission for COVID-19 in HIV patientsAntonio Di Biagio, Elena Ricci, Leonardo Calza, et al.
Viruses|July 29, 2020
Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in ItalyLavinia Fabeni, Maria Mercedes Santoro, Patrizia Lorenzini, et al.
HIV Clinical Trials|March 21, 2019
Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjectsAmedeo F Capetti, Giuseppe V De Socio, Maria V Cossu, et al.
AIDS (London, England)|March 15, 2019
Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapyAntonella Castagna, Stefano Rusconi, Roberto Gulminetti, et al.
BMC Infectious Diseases|October 2, 2017
A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks' observational dataAmedeo F Capetti, Maria Vittoria Cossu, Giancarlo Orofino, et al.
HIV Clinical Trials|February 13, 2014
Genotypic determination of HIV tropism in a cohort of patients perinatally infected with HIV-1 and exposed to antiretroviral therapyAntonio Di Biagio, Andrea Parisini, Bianca Bruzzone, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 27, 2021
Five Years With Dolutegravir Plus Lamivudine as a Switch Strategy: Much More Than a Positive FindingArturo Ciccullo, Vanni Borghi, Andrea Giacomelli, et al.
HIV Medicine|July 28, 2021
Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohortMassimiliano Fabbiani, Barbara Rossetti, Arturo Ciccullo, et al.
Diabetes/Metabolism Research and Reviews|July 13, 2022
Inflammation and vascular dysfunction: The negative synergistic combination of diabetes and COVID-19Andrea Mario Bolla, Cristian Loretelli, Laura Montefusco, et al.
Pageof 20

Showing results (131-140 of 192) with videos related to

Sort By:
Pageof 20
AIDS (London, England)|January 26, 2026
Durable efficacy of dolutegravir/rilpivirine switch in subjects with HIV RNA <50 copies/mL and history of K103N mutationGraeme Moyle, Lambert Assoumou, Nathalie De Castro, et al.
AIDS (London, England)|August 16, 2020
Factors associated with hospital admission for COVID-19 in HIV patientsAntonio Di Biagio, Elena Ricci, Leonardo Calza, et al.
Viruses|July 29, 2020
Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in ItalyLavinia Fabeni, Maria Mercedes Santoro, Patrizia Lorenzini, et al.
HIV Clinical Trials|March 21, 2019
Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjectsAmedeo F Capetti, Giuseppe V De Socio, Maria V Cossu, et al.
AIDS (London, England)|March 15, 2019
Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapyAntonella Castagna, Stefano Rusconi, Roberto Gulminetti, et al.
BMC Infectious Diseases|October 2, 2017
A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks' observational dataAmedeo F Capetti, Maria Vittoria Cossu, Giancarlo Orofino, et al.
HIV Clinical Trials|February 13, 2014
Genotypic determination of HIV tropism in a cohort of patients perinatally infected with HIV-1 and exposed to antiretroviral therapyAntonio Di Biagio, Andrea Parisini, Bianca Bruzzone, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 27, 2021
Five Years With Dolutegravir Plus Lamivudine as a Switch Strategy: Much More Than a Positive FindingArturo Ciccullo, Vanni Borghi, Andrea Giacomelli, et al.
HIV Medicine|July 28, 2021
Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohortMassimiliano Fabbiani, Barbara Rossetti, Arturo Ciccullo, et al.
Diabetes/Metabolism Research and Reviews|July 13, 2022
Inflammation and vascular dysfunction: The negative synergistic combination of diabetes and COVID-19Andrea Mario Bolla, Cristian Loretelli, Laura Montefusco, et al.
Pageof 20